Clicky

Telesis Bio, Inc.(TBIO)

Description: Codex DNA is a synthetic biology company focused on enabling researchers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets. Codex DNA’s synthetic biology solution addresses the bottlenecks across the multi-step process of building DNA and mRNA, as well as the significant limitations of existing solutions that prevent the rapid building of virtually error-free DNA and mRNA at a useable scale. A key part of Codex DNA’s solution is the BioXp™ system, an end-to-end automated workstation that fits on the benchtop and is broadly accessible due to its ease-of-use and hands-free automation. Codex DNA believes the BioXp™ system can democratize synthetic biology by simplifying the process of building DNA and mRNA, thereby accelerating the discovery, development, and production of novel high-value products, including antibody-based biologics, mRNA-based vaccines and therapeutics and precision medicines.


Keywords: Biotechnology Biopharmaceutical Life Sciences Emerging Technologies Biology Molecular Biology Gene Expression Synthetic Biology Molecular Genetics Messenger RNA

Home Page:

TBIO Technical Analysis

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 0
IPO Date: 2021-06-18
Fiscal Year End: December
Full Time Employees: 212
Back to stocks